Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drug

Hulio(Cf)(Adalimumab-Fkjp)Viatris Inc. logoVTRS

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Viatris Inc.

$75K

Medicare cost, 2024

Medicare drug plans spent $74,814 on Hulio(Cf) (adalimumab-fkjp) in 2024, for 12 prescriptions and refills. At about $6,235 per prescription it is a high-cost drug. It is made by Viatris Inc. (VTRS).

Medicare cost, 2024

$75K

Prescriptions

12

$6,234.51 per claim

Patients

-

1 prescribers

Total spending, 2024

$75K

- per patient

Questions and answers

How much does Medicare spend on Hulio(Cf)?

Medicare prescription drug plans paid $75K for Hulio(Cf) in 2024, for 12 prescriptions and refills to - patients. The average cost per claim was $6,234.51.

Which state spends the most on Hulio(Cf)?

Pennsylvania had the highest Medicare cost for Hulio(Cf) in 2024: $75K for 12 claims.

Who prescribes Hulio(Cf) the most?

Shawnaa L Rutkowsky, nurse practitioner in Greensburg, PA, had the highest Medicare cost for Hulio(Cf) in 2024: 12 claims costing $75K.

Who makes Hulio(Cf)?

Hulio(Cf) is made by Viatris Inc. (VTRS), listed in the Medicare spending data as Mylan Spec/Bioc.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Hulio(Cf), 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Shawnaa L Rutkowsky Greensburg, PANurse Practitioner12Under 11$75K

Prescriber data by year

YearPrescribersClaimsPatientsCost
2024112-$75K

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Mylan Spec/BiocVTRS logoVTRS12$75K

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube